18 September 2014

IPO Affimed on NASDAQ

+ 4 other team members
De Brauw Blackstone Westbroek advised Affimed on its IPO on the NASDAQ Global Market. Affimed will offer a total of 9,200,000 shares, with the deal pricing on 12 September 2014 at USD 7,00 per share.

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies.

De Brauw acted as Dutch counsel to Affimed and Constantijn Voogt was lead partner.